… genotype strongly affects the levels of cerebrospinal fluid amyloid-β 1-42 … Alzheimer's disease
CSF biomarkers in 1233 cognitively normal subjects aged 40–85 years. Alzheimer disease…

… criteria in order to characterize the disease at a pre-dementia stage. It was proposed to
take into account neuroimaging biomarkers and cerebrospinal fluid (CSF) analysis of amyloid …

… of Alzheimer's disease (AD), which has been translated into an ongoing development of
disease-… Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). The …

… -modifying drugs have created a need for biomarkers that reflect core elements of the
disease process. Here, we review the development of candidate cerebrospinal fluid (CSF) and …

… in disease diagnosis and prognosis, and assess disease risk … have demonstrated that
Alzheimer's disease pathology can … the most promising cerebrospinal fluid biomarkers, highlights …

… Although protein content is lower in cerebrospinal fluid (CSF) than in serum, CSF is an ideal
source for developing viable biomarkers in AD as it directly interacts with the extracellular …

… in Alzheimer's disease as … Alzheimer's disease. Also, CSF levels in a large group of
patients with a diversity of neurological diseases showed overlap with CSF levels in Alzheimer's …

… between mild cognitive impairment (MCI) and incipient Alzheimer's disease (AD). We
show that a combination of three cerebrospinal fluid biochemical markers, total-tau, phospho-tau …

… We hypothesized that etiologic biomarkers for AD such as cerebrospinal fluid (CSF) protein
profiles can improve the antemortem characterization of AD and non-AD pathology in older …

… An accurate and early diagnosis of Alzheimer’s disease (AD) is important to select optimal …
been made in the development and validation of cerebrospinal fluid (CSF) biomarkers for the …